Circassia Pharmaceuticals plcCompany Review & Valuation

82C
Börse Frankfurt
Latest Price
0.38EUR
Market Capitalization
160.59mEUR

About Circassia Pharmaceuticals plc

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United StatShow more es, the United Kingdom, and Germany, as well as through a network of partners internationally. The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide. It is also developing various novel specialty treatments for COPD, including Spiriva substitute, Novel LABA/LAMA formulation, and novel COPD therapy formulation. In addition, the company' development pipeline includes a range of treatments for allergies, such as cat allergy, grass allergy, house dust mite allergy, and ragweed allergy. It has a collaboration agreement with AstraZeneca to promote Tudorza for COPD treatment, and has the US commercial rights to late-stage COPD product Duaklir. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom. Show less

Industry
HQ Location
Oxford, United Kingdom

Stock Price

Price data not available for Circassia Pharmaceuticals plc.

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top